Title of article
Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study
Author/Authors
Jürgen Rehm، نويسنده , , Patrick Gschwend، نويسنده , , Thomas Steffen، نويسنده , , Felix Gutzwiller، نويسنده , , Anja Dobler-Mikola، نويسنده , , Ambros Uchtenhagen، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2001
Pages
4
From page
1417
To page
1420
Abstract
Background
Heroin-assisted substitution treatment for severely opioid-dependent drug users has been available in Switzerland since 1994. Our aim was to ascertain the feasibility, safety, and efficacy of this treatment.
Methods
We did a cohort study in 21 community outpatient treatment centres. We assessed 1969 opioid-dependent drug users, who began heroin-assisted substitution treatment between January, 1994, and December, 2000, to ascertain admission and discharge patterns, and patient characteristics. We also followed up a subset of 237 patients who began treatment between Jan 1, 1994, and March 31, 1995, and who stayed with the programme for at least 18 months. We used questionnaires, interviews, and medical examinations done at entry and after 6, 12, and 18 months to assess somatic and mental health, social integration, and treatment outcomes.
Findings
More than 70% (1378) of patients remained in treatment for more than a year. Treatment showed positive effects with respect to health and social outcomes. A long stay in treatment was related to a higher chance of starting abstinence-oriented therapy than a short stay.
Interpretation
Heroin-assisted substitution treatment might be an effective option for chronically addicted patients for whom other treatments have failed.
Journal title
The Lancet
Serial Year
2001
Journal title
The Lancet
Record number
566508
Link To Document